Return on drug R&D dropping


The pharma industry is getting less and less return on investment in R&D, according to a report. But the trend seems to be bottoming out and – on a more positive note – there are more compounds going into late stage development.

Consultants Deloitte and data firm Thomson Reuters looked at twelve pharma companies and estimated the projected financial returns from the R&D investment in their late stage pipeline, comprising products that are in Phase III trials, but have yet to be approved for marketing.

They found that the return fell from 7.7% in 2010–11 to 7.2% in 2011–12, but the number of number of compounds entering the late stage pipeline more than doubled from 35 to 78.

Overall, the results present a mixed bag for the optimists. The number of approvals increased from 32 to 41, but the total forecast sales of all approvals fell by a third, from $309 billion (£192 billion) to $211 billion. Meanwhile, the total forecast sales of candidates in late stage pipelines declined from $1,370 billion in 2010 to $1,050 billion in 2012.


Related Content

Roadmap to reward pharma for creating new antibiotics unveiled

19 May 2015 News and Analysis

news image

Report recommends large up-front payments and an innovation fund for blue skies research to tackle microbial resistance

The hunt for innovation

31 January 2014 Premium contentFeature

news image

Big pharma companies are embracing a more open and collaborative approach. Nuala Moran discovers who’s working with whom

Most Read

US government science institute's one time police chief linked to campus meth lab

31 July 2015 News and Analysis

news image

Explosion injuring a member of the National Institute of Standards and Technology's security force uncovered methamphetamine ...

Antifreeze polymer protects cells as they thaw

29 July 2015 Research

news image

Simple synthetic polymer found to enhance cryopreservation of red blood cells by inhibiting ice crystal growth

Most Commented

(–)-Jiadifenolide

27 July 2015 Organic Matter

news image

BRSM wonders what makes a route so good it becomes the last total synthesis of a complex target

Butterfly population collapse prompts lawsuit against EPA

5 March 2015 News and Analysis

news image

US agency criticised for failing to investigate link between glyphosate and the dwindling monarch butterfly population